Dr. Krista Lanctot
Vice-Chair, Basic & Clinical Sciences
Geriatric Psychiatry
Contact Info
T: (416) 480-6100
Sunnybrook Health Sciences Centre
2075 Bayview Ave
Toronto, ON, M4N 3M5
Appointment Status Primary

Dr. Krista L. Lanctôt is a clinical pharmacologist, having received her PhD from the Department of Pharmacology, University of Toronto in 1998, with additional training in pharmacoepidemiology. She is currently a Senior Scientist in the Brain Sciences Research Program at Sunnybrook Health Sciences Centre, the Head of Neuropsychopharmacology Research and the Executive Director of the Medical Outcomes and Research in Economics (MORE®) Research Centre, a research group focusing on outcomes research. She is a Full Professor in the Departments of Psychiatry and Pharmacology, University of Toronto, Toronto, Ontario, Canada.

Dr. Lanctôt is an active researcher in clinical pharmacology and pharmacoeconomics and has published over 150 manuscripts. Since coming to Sunnybrook over 20 years ago, her research has focused on Alzheimer’s disease, and depression and cognitive changes in those with coronary artery disease and post-stroke. She also teaches at undergraduate and graduate levels through her appointment at the University of Toronto. In October 2019 she joinded the Department of Psychiatry's Executive Committee in the role of Vice Chair, Clinical and Basic Sciences.



Neuropsychopharmacology research group


MORE research group


U of T profile - pharmacology and toxicology


Toronto Rehab - Research


Heart and Stroke Foundation Centre for Stroke Recovery



Other Links
See current publications list at PubMed.


Research Synopsis

Neuropsychiatric symptoms associated with illness include mood changes, apathy, aggression and cognitive changes. These are common sequelae of many central nervous system disorders such as dementia, traumatic brain injury, cerebrovascular disease and stroke. Dr. Lanctôt’s goal is to optimize the psychopharmacological management of these neuropsychiatric symptoms.

Current research addresses this goal by determining underlying neurobiology of neuropsychiatric symptoms, examining predictors of treatment response, using novel pharmacological agents, and carefully considering adverse drug events. Dr. Lanctôt’s early focus was on neurobiology of behavioural disorders associated with dementia. The goal of this research was to determine if behavioural subtypes can be linked to underlying neurochemical or neuropathologic dysfunction. A variety of tools including neuroimaging, pharmacogenetics and pharmacologic challenges are used in combination with pharmacotherapeutic trials. This research will contribute to our understanding of the link between dysfunction in various neurotransmitters and neuropsychiatric symptoms. As such, it may allow Dr. Lanctôt’s team to predict response to medications based on behavioral subtypes. At a broader level, it can provide the background for novel therapies.

A second focus of research evaluates the impact of pharmacologic treatments at a population level, which includes measuring relevant health outcomes, quality of life and modelling cost-benefit, cost-effectiveness and cost-utility of pharmacotherapies.